Combination Treatment
AssigneeDuke University
InventorsDarell D. Bigner, Matthias Gromeier, Smita Nair, Vidyalakshmi Chandramohan
Life of this patent
Estimating the term…
Abstract
Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Combination with immune checkpoint inhibitors increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioglastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.
Claims35
A method of treating a tumor in a patient, comprising:
- administering to the patient a PVSRIPO chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame;
- and
- administering an anti-PD-1 antibody, whereby the patient is treated.
A method of treating a tumor in a patient, comprising:
- administering to the patient a PVSRIPO chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame;
- and
- administering an anti-PD-L1 antibody to the patient, whereby the patient is treated.
A kit in a divided container for treating a tumor that expresses NECL5 (nectin-like protein 5), comprising:
- a PVSRIPO chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame;
- and
- an anti-PD-1 antibody, wherein the chimeric poliovirus construct and the antibody are in distinct vessels of the divided container.
A kit in a divided container for treating a tumor that expresses NECL5 (nectin-like protein 5), comprising:
- a PVSRIPO chimeric poliovirus construct which comprises a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame;
- and
- an anti-PD-L1 antibody, wherein the chimeric poliovirus construct and the antibody are in distinct vessels of the divided container.
A composition comprising a PVSRIPO chimeric poliovirus construct and an anti-PD-1 antibody;
- wherein the chimeric poliovirus construct comprises a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame.
A composition comprising a PVSRIPO chimeric poliovirus construct and an anti-PD-L1 antibody;
- wherein the chimeric poliovirus construct comprises a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame.
Dependencies are inferred from the claim text.